Pharmacological Development Of Synthetic Analogues Of Cytochrome P450-mediated Omega-3 Fatty Acid Epoxides As Novel Anti-metastatic Agents
Funder
National Health and Medical Research Council
Funding Amount
$865,174.00
Summary
Dietary ?-3 and ?-6 fatty acids respectively decrease and increase the risk of cancer spread, or metastasis. We have found that ?-3 fatty acid epoxide metabolites inhibit the growth and migration of tumour cells. We have prepared derivatives of these ?-3 epoxides that retain anti-cancer properties in cells. In this project we will develop analogues of these ?-3 epoxides that are suitable for in vivo testing in animal models of breast cancer metastasis as a new class of potential anti-metastatic ....Dietary ?-3 and ?-6 fatty acids respectively decrease and increase the risk of cancer spread, or metastasis. We have found that ?-3 fatty acid epoxide metabolites inhibit the growth and migration of tumour cells. We have prepared derivatives of these ?-3 epoxides that retain anti-cancer properties in cells. In this project we will develop analogues of these ?-3 epoxides that are suitable for in vivo testing in animal models of breast cancer metastasis as a new class of potential anti-metastatic drugs.Read moreRead less
Development Of Novel Anti-cancer Agents Based On Cytochrome P450-mediated Epoxides Of Omega-3 Fatty Acids
Funder
National Health and Medical Research Council
Funding Amount
$949,433.00
Summary
There are few effective treatments for advanced breast cancer. Dietary ?-3 and ?-6 fatty acids respectively decrease and increase the risk of cancer spread. We have found that ?-3 fatty acid epoxide metabolites inhibit the growth of tumour cells and have prepared analogues that are highly active in vivo in animal models of breast cancer. This project will improve and optimise these agents that hold promise as a new class of anti-cancer drugs with the potential to treat advanced disease.
The key goal of my research is to understand the role of protein phosphorylation in controlling metabolism, with a special emphasis on the structure and function of members of the AMP-activated protein kinase (AMPK) pathway. This is important because the function and survival of all organisms is dependent on the dynamic control of energy metabolism, with energy demand matched to energy supply.
Therapeutic Strategies And Screening Methods For PKC Epsilon Antagonists In The Treatment Of Type 2 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$157,375.00
Summary
Type 2 diabetes is a chronic disease affecting over a million Australians and hundreds of millions of people worldwide. Its prevalence is rising due to several factors such as an increase in caloric intake, the aging of the population, and the common sedentary lifestyle of Western civilization. Type 2 diabetes occurs when the pancreas is unable to produce enough insulin for the body to cope with rising blood glucose levels after a meal, and has been strongly linked to obesity. We have now shown ....Type 2 diabetes is a chronic disease affecting over a million Australians and hundreds of millions of people worldwide. Its prevalence is rising due to several factors such as an increase in caloric intake, the aging of the population, and the common sedentary lifestyle of Western civilization. Type 2 diabetes occurs when the pancreas is unable to produce enough insulin for the body to cope with rising blood glucose levels after a meal, and has been strongly linked to obesity. We have now shown that an enzyme found in the pancreas becomes inappropriately activated under conditions of fat oversupply, and plays an important role in the development of defects in insulin release from the pancreas in response to glucose. Excitingly, we have also shown that inhibition of this enzyme can partly reverse these defects once they have been established. We now intend to further validate this enzyme as a drug target by determining the optimum dosing regimen for the treatment of type 2 diabetes in a mouse model, and testing whether this approach can be used in conjunction with previously-developed drugs which promote insulin action, to improve bood glucose handling better than either treatment alone. This would promote the enzyme as a therapeutic strategy in the treatment of Type 2 diabetes. We also plan to develop a high throuhput screen to identify novel inhibitors of the enzyme, which will further increase the attractiveness of the project to pharmaceutical companies, who are better able to implent full commercialization of our findings.Read moreRead less
The Role Of Plasma Membrane Microdomains In Regulating Ras-dependent Raf Activation
Funder
National Health and Medical Research Council
Funding Amount
$216,100.00
Summary
In human cancers one or more of the signaling pathways leading from growth factor receptors at the cell surface to the nucleus where cell division is initiated are subverted. For example, a protein called Ras, that regulates a series of major signaling pathways, is mutated in 25% of all human tumours. This leaves Ras and the signaling pathways permanently switched on causing uncontrolled cell proliferation. Our previous work has demonstrated that Ras must be attached to the inner surface of the ....In human cancers one or more of the signaling pathways leading from growth factor receptors at the cell surface to the nucleus where cell division is initiated are subverted. For example, a protein called Ras, that regulates a series of major signaling pathways, is mutated in 25% of all human tumours. This leaves Ras and the signaling pathways permanently switched on causing uncontrolled cell proliferation. Our previous work has demonstrated that Ras must be attached to the inner surface of the cell membrane in order to function properly. This project now seeks to understand exactly how Ras attaches to and interacts with specific sites in the plasma membrane. Its is becoming clear that different isoforms of Ras, called H-, N- and K-ras have different functions in the cell which may in turn result from their different sites of attachment to the cell membrane. This is important because by understanding the precise micro-environment in which the different Ras proteins operate and how they activate subsequent proteins in their signaling networks we will be in a good position to design drugs that selectively compromise the function of each specific Ras isoform. A highly relevant example is provided by K-ras which is mutated in 90% of all pancreatic cancers and 50% of all colon cancers. Clearly the clinical impact of a drug that could selectively neutralise K-Ras function in these tumours is potentially enormous.Read moreRead less
Ras Signalling And Cholesterol Efflux From Late Endosomes
Funder
National Health and Medical Research Council
Funding Amount
$276,598.00
Summary
Accumulation of cholesterol is a hallmark of early atherosclerotic lesions, known as foam cell formation. Hence the stimulation of cholesterol removal (efflux) from macrophages has great therapeutic potential. High Density Lipoproteins (HDL) and apolipoprotein A-I (apoA-I) stimulate efflux via activation of HDL-apoA-I receptors and poorly understood signalling pathways. This application is investigating the role of the Ras-MAPK signalling pathway in promoting efflux from late endosomes.
Role Of Sphingosine Kinase 1 In PP2A-associated Tumorigenesis
Funder
National Health and Medical Research Council
Funding Amount
$522,994.00
Summary
Defects in protein phosphatase 2A (PP2A) are widely associated with the development of solid tumors and leukemia. The precise mechanisms whereby defects in PP2A lead to cancer, however, remain undefined. We have recently identified that the oncogenic protein sphingosine kinase 1 (SK1) as a target of PP2A. In this study we will examine the role of SK1 in PP2A-associated cancers. Successful outcomes in these studies will establish SK1 as a target for therapeutic intervention in these cancers.
Mechanisms Of Regulation And Biological Roles Of Sphingosine Kinase 2
Funder
National Health and Medical Research Council
Funding Amount
$517,989.00
Summary
We have identified that a protein called sphingosine kinase 2 (SK2) is a potential target for anti-cancer therapies. Our preliminary studies indicate that phosphorylation of SK2 controls its function. In this proposal we will define how phosphorylation alters SK2 function so that potential therapies may be developed to target this process.